Cover Image
市場調查報告書

高苯丙胺酸血症:全球臨床實驗檢討

Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 301441
出版日期 內容資訊 英文 162 Pages
訂單完成後即時交付
價格
Back to Top
高苯丙胺酸血症:全球臨床實驗檢討 Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月27日 內容資訊: 英文 162 Pages
簡介

本報告提供高苯丙胺酸血症的治療藥相關臨床實驗調查分析,提供臨床實驗數及被實驗人數,階段及Phase別狀況,有潛力的企業,正在開發的治療藥資訊,臨床實驗簡介等,為您概述為以下內容。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東·非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:代謝障礙臨床實驗中高苯丙胺酸血症的比例

G7各國的臨床實驗:Phase別

G7各國的臨床實驗:各階段

E7各國的臨床實驗:代謝障礙臨床實驗中高苯丙胺酸血症的比例

E7各國的臨床實驗:Phase別

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

贊助商各類型臨床實驗

有潛力的贊助商

  • 參與高苯丙胺酸血症的治療藥臨床實驗的主要企業

有前途藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • TEIJIN FIBERS
    • 武田藥品工業
    • Sanofi
    • AstraZeneca PLC
    • 富士藥品
    • BioMarin Pharmaceutical Inc.
    • 三和化學研究所
    • Nuon Therapeutics, Inc.
    • 日本煙草產業
    • BioCryst Pharmaceuticals, Inc.
  • 主要大學·研究機關·醫院臨床實驗概要
    • 九州大學
    • University of Otago
    • China Medical University Hospital
    • National Cerebral and Cardiovascular Center
    • 鳥取大學醫學系附屬醫院
    • 福島縣立醫科大學
    • The University of Texas Health Science Center at Houston
    • The Medical Center Leeuwarden
    • 順天堂大學醫學系
    • 綠丘醫院

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4617CTIDB

GlobalData's clinical trial report, "Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperphenylalaninemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphenylalaninemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Hyperphenylalaninemia Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Clinical Trial Profile Snapshots 29

Appendix 160

  • Abbreviations 160
  • Definitions 160
  • Research Methodology 161
  • Secondary Research 161
  • About GlobalData 162
  • Contact Us 162
  • Source 162

List of Tables

List of Tables

  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Hyperphenylalaninemia Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Phase, 2017* 20
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Hyperphenylalaninemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures

List of Figures

  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 9
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
  • Hyperphenylalaninemia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 12
  • Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
  • Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Hyperphenylalaninemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28
  • GlobalData Methodology 161
Back to Top